The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.The phase 1/phase 2 trial did not meet its primary efficacy endpoint of objective response rate; however, the combination conferred a 12-month OS rate of 52.7% — which
WEDNESDAY, April 5, 2023 (HealthDay News) For patients with Parkinson disease (PD), racial and ethnic minorities have worse health-related quality of life (HRQoL) than White patients, according to a